RBC Capital Markets adds biotech firm to UK small-cap portfolio as Iran conflict reshapes energy outlook

RBC Capital Markets has made a single change to its ten-stock UK small and mid-cap (SMID) portfolio, swapping out homewares retailer Dunelm Group PLC (LSE:DNLM) for Oxford BioMedica PLC (LSE:OXB), the Oxford-based gene therapy manufacturer. It rates the latter 'outperform' with a price target of 1,170p against a current price of 602p, implying a 94% total return.